Kairos Pharma presents preclinical data on KROS 101 at AACR-JCA; shows tumor reduction in melanoma models

Kairos Pharma, LTD.

KROS 101, a GITR agonist, enhanced T cell infiltration and proliferation in mouse melanoma models and human glioblastoma in vitro.
In a preclinical study, KROS 101 reduced melanoma tumor in human GITR knock-in mouse model vs. the GITR antibody TRX518.
Data presented at the 13th AACR-JCA Joint Conference from Feb 1-5, 2025 in Maui, Hawaii.
CEO Dr. John S. Yu and VP R&D Dr. Ramachandran Murali co-presented; potential for melanoma and glioblastoma therapy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.